Role of viral RNA and lipid in the adverse events associated with the 2010 Southern Hemisphere trivalent influenza vaccine  by Rockman, Steve et al.
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In Australia,  during  the  2010  Southern  Hemisphere  (SH)  inﬂuenza  season,  there  was  an  unexpected
increase  in post-marketing  adverse  event  reports  of  febrile  seizures  (FS)  in children  under  5  years  of  age
shortly  after vaccination  with  the  CSL  2010  SH  trivalent  inﬂuenza  vaccine  (CSL  2010 SH  TIV)  compared
to  previous  CSL  TIVs and  other  licensed  2010  SH  TIVs.  In an  accompanying  study,  we described  the
contribution  to  these  adverse  events  of  the  2010  SH  inﬂuenza  strains  as expressed  in the  CSL  2010  SH TIV
using  in  vitro  cytokine/chemokine  secretion  from  whole  blood  cells  and  induction  of  NF-B  activation  in
HEK293  reporter  cells.  The  aim of  the present  study was  to  identify  the  root  cause  components  that  elicited
the  elevated  cytokine/chemokine  and  NF-B  signature.  Our  studies  demonstrated  that the pyrogenic
signal  was  associated  with  a heat-labile,  viral-derived  component(s)  in  the  CSL  2010  SH  TIV. Further,  it
was  found  that  viral  lipid-mediated  delivery  of  short,  fragmented  viral  RNA  was the  key  trigger  for  the
increased  cytokine/chemokine  secretion  and NF-B  activation.  It is likely  that the  FS reported  in  children
<5  years  were  due  to a combination  of  the  new  inﬂuenza  strains  included  in the 2010 SH TIV  and  the  CSL
standard  method  of manufacture  preserving  strain-speciﬁc  viral  components  of the  new  inﬂuenza  strains
(particularly  B/Brisbane/60/2008  and  to a lesser  extent  H1N1  A/California/07/2009).  These  combined  to
heighten  immune  activation  of innate  immune  cells,  which  in a small  proportion  of children  <5  years
of  age  is  associated  with  the  occurrence  of FS.  The  data  also  demonstrates  that  CSL  TIVs  formulated
with  increased  levels  of splitting  agent  (TDOC)  for the  B/Brisbane/60/2008  strain  can  attenuate  the  pro-
inﬂammatory  signals  in  vitro,  identifying  a potential  path  forward  for generating  a  CSL  TIV indicated  for
use  in  children  <5 years.
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1. Introduction
Vaccination with an inactivated preparation (TIV or more
recently quardrivalent inactivated vaccine) of the most prevalent
circulating inﬂuenza strains is an approved and effective method
for preventing seasonal inﬂuenza [1]. Trivalent inﬂuenza vaccines
(TIVs), as with other vaccines, are typically associated with mild
adverse events (AEs) [2]. The most frequently reported AEs asso-
ciated with inﬂuenza vaccination in both children and adults is
injection site pain, which generally resolves within 2 days with-
out clinical intervention. Systemic symptoms such as fever, malaise
and myalgia are less common, and appear to occur more frequently
in individuals who have had no prior exposure to inﬂuenza virus
antigens, either via vaccination or infection [3].
The AEs associated with inﬂuenza vaccination are often simi-
lar to the systemic symptoms associated with inﬂuenza infection
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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e.g. fever, headache, myalgia, listlessness, etc.), thus implicating
he likely involvement of virus-derived components as medi-
tors of the vaccine-related AEs. During inﬂuenza infection,
ocal and systemic symptoms largely result from the action
f endogenous mediators such as pro-inﬂammatory cytokines
e.g. IL-1, TNF- and IL-6), which are released by innate
mmune cells such as antigen presenting cells (APCs) following
timulation by pathogen-associated molecular patterns (PAMPs)
4–6].
In the 2010 SH season, CSL 2010 SH TIV, also known as
luvax® 2010 SH, was associated with an unexpected increase
n post-marketing reports of fever and febrile convulsions, com-
ared to previous seasons, predominantly in children <5 years
f age [7,8]. The accompanying study Rockman et al. [9], deter-
ined that the introduction of the new strains in the Fluvax®
010 SH correlated with an increase in in vitro cytokine/chemokine
ecretion in a proportion of paediatric whole blood donors as
ell as displayed elevated NF-B activation in a NF-B SEA-
orter HEK293 cell assay (NF-B HEK 293 assay) [9]. The current
tudy aimed to identify the root cause components that may  have
ontributed to the increased cytokine/chemokine and NF-B sig-
ature observed in the whole blood and NF-B HEK 293 assays
espectively.
Previous attempts to identify the components of inﬂuenza
irus that can elicit pyrogenic responses have yielded conﬂicting
esults [10–12]. Disruption of intact virions by treatment with
nzyme (bromelain), detergent or ether, produced a noticeable
eduction in pyrogenicity, suggesting that intact/whole virus can
ontribute to the pyrogenic proﬁle of TIVs [13–16]. However, puri-
ed surface proteins [17,18], viral core components containing the
ucleoprotein (NP), polymerase complex and RNA [13] have also
een implicated as potential inﬂuenza virus-associated pyrogens,
hereas puriﬁed NP and matrix proteins were shown to lack pyro-
enic properties [13].
The current study demonstrates that the increased in vitro
ytokine/chemokine and NF-B signals detected in the CSL 2010
H TIV compared to other 2010 SH TIVs and previous CSL TIVs
ere associated with a heat-labile, viral-derived component(s).
urthermore, the data proposes that lipid-mediated delivery of
ragmented RNA to APCs elicited an elevated cytokine/chemokine
nd NF-B activation cascade that may  have contributed to the
ccurrence of FS in a proportion of children <5 years in the 2010 SH
eason.
. Materials and methods
.1. TIV and MPH  preparations tested
TIVs tested in the in vitro assays with the appropriate con-
rols as described below: CSL 2005/2006–2011/12 TIV, CSL
anvax® monovalent H1N1, re-engineered CSL 2010 SH TIVs (as
escribed), TIVs made by other manufacturers – Comparator A
licensed split virion 2010 SH TIV), Comparator B (licensed sub-
nit 2010/11 NH TIV) and MPHs: H1N1 (A/Brisbane/59/2007
nd A/California/07/2009), H3N2 (A/Uruguay/716/2007,
/Wisconsin/15/2009 and A/Victoria/210/2009) and B strains
B/Brisbane/60/2008 and B/Florida/04/2006).
.2. In vitro detection of cytokine/chemokine in paediatric blood
nd NF-B HEK293 assayMaterials and methods for assessing in vitro induction of
ytokine/chemokine in paediatric whole blood assays (WBA) and
F-B HEK 293 assay are described in an accompanying manuscript
9].2 (2014) 3869–3876
2.3. Protein estimation
The protein concentration of TIVs and MPHs was determined
using a detergent compatible, modiﬁed Lowry assay kit (BioRad,
DC protein assay kit) as per manufacturer’s instructions.
2.4. RNA quantitation
RNA was  puriﬁed using the QIAamp viral RNA kit (Qiagen,
USA) according to manufacturer’s instructions, except that car-
rier RNA was omitted (see http://www.qiagen.com/products/
rnastabilizationpuriﬁcation/cellviralrnapuriﬁcationsystems/
qiaampviralrnaminikit.aspx for details). RNA was quantiﬁed using
either a NanoDrop spectrophotometer (ThermaScientiﬁc, USA) or
a 2100 Bioanalyze (Agilent Technologies Inc, USA). All results were
normalised to protein levels to enable direct comparison between
samples.
2.5. Enzymatic treatment of TIVs and MPHs and transfection of
RNA
TIV and MPH  samples were normalised to 10.6 g HA/mL and
then incubated with either RNase A (Qiagen, used at 50 g/ml
ﬁnal concentration), benzonase (Sigma, used at 1.25 U/l ﬁnal
concentration), phospholipase C (Sigma, used at 200 U/l  ﬁnal
concentration), or proteinase K (Sigma, used at 5 g/ml ﬁnal con-
centration) for 1 hr at 37 ◦C. See Supplemental Materials and
Methods for further details.
2.6. Lipid quantitation by HPLC
Inﬂuenza TIV and MPH  samples were analysed using an Agilent
1100 HPLC system equipped with a Shimadzu ELSD LT-II evapora-
tive light scattering detector (ELSD). See Supplemental Materials
and Methods for further details.
2.7. Statistical analyses
See Supplemental Materials and Methods for further details.
3. Results
Initial root cause investigations into the AEs in children <5 years
receiving the CSL 2010 SH TIV led to the hypothesis that differences
in CSL’s standard TIV manufacturing process, as compared to other
manufacturers’ processes, in combination with strain-speciﬁc char-
acteristics associated with the three new strains introduced into the
2010 SH TIV (compared to previous seasons CSL TIV’s) contributed
to the increase in reports of FS in children <5 years [9,19]. In order
to test this hypothesis, a series of in vitro studies, using either pae-
diatric WBAs or the NF-B HEK 293 assay [9,19] were performed
to identify the component(s) within the CSL 2010 SH TIV that may
have contributed to its pyrogenic potential.
3.1. Cytokine/chemokine and NF-B responses induced in vitro by
CSL TIVs are heat labile
TIVs and MPHs were heated to either 56 ◦C or 65 ◦C or 90 ◦C
for 30 mins and then allowed to cool to RT before being tested
in the paediatric WBA  (Fig. 1A) or the NF-B HEK 293 cell assay
(Fig. 1B).
Heating the CSL or comparator A TIVs to 56 ◦C did not affect
induction of cytokines/chemokines. However, heating to 65 ◦C
or 90 ◦C reduced the levels of cytokines/chemokines to back-
ground levels (Fig. 1A). MPHs behaved similarly following heat
treatment. However, whereas heating A/California/07/2009 MPH
S. Rockman et al. / Vaccine 32 (2014) 3869–3876 3871
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Fig. 1. Induction of IL-1 secretion and NF-B activation in vitro following stimulation with heat treated, CSL TIVs and MPHs. (A) Induction of IL-1 following in vitro
stimulation of paediatric whole blood cells with CSL TIVs, comparator A TIV or MPHs (H1N1: A/California/07/2009; B: B/Brisbane/60/2008) which had been heated at 56 ◦C,
65 ◦C or 90 ◦C as indicated. Data presented as the mean (pg/mL) and SD of 6 paediatric donors. (B) Induction of NF-B activation (O.D. 405 nm)  in NF-B HEK 293 cells in
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aesponse to CSL SH 2010 TIV or MPH  (B/Brisbane/60/2008) pre-treated at 56 ◦C, 65
ssays.
o either 56 ◦C or 65 ◦C or 90 ◦C for 30 mins, resulted in a pro-
ressively greater reduction in the IL-1 cytokine response, the
/Brisbane/60/2008 MPH  still induced a strong IL-1 response fol-
owing 65 ◦C treatment with signiﬁcant abrogation observed only
fter 90 ◦C heating (Fig. 1A). Similar response patterns following
eat treatment were observed for IL-6, TNF-, IL-1RA, IL-8, MIP-1,
CP-1 and IP-10 (data not shown).
Consistent with the paediatric WBA  data, heating the CSL 2010
H TIV to 65 ◦C signiﬁcantly reduced NF-B activation in NF-B HEK
93 cells (Fig. 1B). However, unlike the ﬁndings in the paediatric
BAs, heating of B/Brisbane/60/2008 MPH  to 65 ◦C signiﬁcantly
educed NF-B activation. The reason for this difference is unclear
ut may  reﬂect differences in the PRR expression patterns and
esponsiveness of heterogeneous whole blood cells as compared to
lonal NF-B HEK 293 cells. The ﬁndings suggest that the signalling
omponent within CSL TIVs and MPHs is heat labile at >65 ◦C, con-
istent with our previous reports [19,20], and indicate that the
ytokine/chemokine inducing component is unlikely bacterially
erived endotoxins (typically heat stable) but rather of viral origin
21].
.2. The role of viral RNA in signal induction
The genomes of viruses possess unique characteristics not
xpressed by mammalian genomes, such as double stranded RNA
dsRNA) or negative single stranded RNA (ssRNA). During infec-
ion, viral nucleic acids are detected by and activate PRRs that
nduce pro-inﬂammatory cytokines (e.g. IL-1, IL-6, TNF-, IL-12).
LR7 and TLR8 in late endosomes and the cytosolic sensor, retinoic
cid inducible gene-I (RIG-I), detect Inﬂuenza virus ssRNA [22].
imilarly, TLR3 in the endosome, RIG-I, melanoma differentiation-
ssociated gene (MDA-5) and RNA-dependent protein kinase R
PKR) in the cytoplasm detect replicating inﬂuenza virus gener-
ted dsRNA [23,24]. The parental NF-B HEK 293 reporter cell0 ◦C as indicated. All samples were tested in triplicate in at least two independent
line constitutively expresses MDA-5, PKR and TLR3 for dsRNA,
TLR8 for ssRNA and RIG-I which recognises both (data not shown).
Thus, detection of viral ssRNA and dsRNA in the CSL TIVs was
examined using both the parental NF-B HEK 293 reporter cell
line or for enhanced detection of speciﬁc ligands using sta-
ble transfectants expressing speciﬁc TLRs (e.g. TLR3, 4, 5, 7, 8,
9).
Measurement of RNA content identiﬁed RNA fragments pre-
dominantly 50–200 nucleotides in length in the CSL SH 2010
TIV and CSL 2010/11 NH TIVs (Fig. 2A). The fragmented nature
of the RNA is consistent with BPL treatment [25], and was  con-
ﬁrmed by RT-PCR using nested primer sets speciﬁc for the HA gene
of A/California/07/2009 and PA gene of B/Brisbane/60/2008 and
B/Florida/04/2006. Products >500 nucleotides in length were not
detected with the majority being <200 nucleotides in length. In
contrast, RNA could not be puriﬁed from Comparator A 2010 SH
TIV (Fig. 2A).
TIVs and MPHs were pre-incubated with nucleases prior to
testing with NF-B HEK 293 reporter cells. Pre-treatment with
RNase A partially reduced NF-B activation (30–50%) by CSL TIVs
but completely reduced NF-B activation by B/Florida/04/2006
and B/Brisbane/60/2008 MPHs (Fig. 2B). Pre-treatment of either
CSL 2010 SH or CSL 2009/10 NH TIVs with an alternative
nuclease, benzonase, resulted in a greater reduction (>70%)
in NF-B activation as compared with RNase A, suggesting
differences between these two nucleases in their ability to
access/degrade residual viral RNA when in a TIV formulation
(Fig. 2B). NF-B activation was also quenched following treat-
ment of CSL 2010 SH TIV and B/Brisbane/60/2008 MPH  with either
2-aminopurine (PKR inhibitor), or baﬁlomycin A (endosomal acid-
iﬁcation inhibitor) (data not shown). Assessment of cell viability
conﬁrmed that the effects of these reagents was pathway speciﬁc
and not due to non-speciﬁc, dose-related cytotoxicity (data not
shown).
3872 S. Rockman et al. / Vaccine 32 (2014) 3869–3876
Fig. 2. Analysis of RNA content and NF-B signalling capacity of CSL TIVs pretreated with nucleases. (A) 2100 Bioanalyzer trace of RNA puriﬁed from CSL 2009 SH and 2010
SH  TIVs or Comparator A (2010 SH TIV made by another manufacturer). Arrow indicates the size of the predominant RNA band. (B) CSL TIVs and MPHs, as indicated, were
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)re-treated with either RNaseA (50 g/ml), benzonase (1.25 U/l) or PBS for 1 hr at
05  nm)  in the NF-B HEK 293 cells.
.3. Signal induced by viral RNA requires lipid-mediated delivery
NF-B HEK 293 cells were cultured in the presence of RNA
xtracted from CSL 2010 SH TIV or CSL 2009/10 NH TIV or
ssociated MPHs. TIV-RNA alone did not induce NF-B activa-
ion. However, NF-B activation was induced when TIV-RNA
as formulated with the cationic, lipid-based transfection agent
LipofectamineTM 2000) to facilitate cellular uptake (Fig. 3). This
uggests that TIV-RNA will only induce NF-B activation fol-
owing lipid-mediated uptake/delivery to the cytoplasm for PRR
ecognition. Furthermore, the addition of LipofectamineTM 2000
o CSL 2010 SH TIV heated to either 65 ◦C or 90 ◦C substantially
estored its ability to activate NF-B (Fig. 4A). However, heat-
reated TIV samples subsequently treated with RNaseA prior to
he addition of the LipofectamineTM 2000 did not signal. This
uggests that fragmented TIV-RNA can only trigger NF-B activa-
ion when heat labile, viral lipid is present for its delivery (with
ipofectamineTM 2000 substituting for viral lipid). Similar ﬁndings
ere observed when examining B/Brisbane/60/2008 MPH  (data not
hown).
Consistent with lipid playing a key role in delivery of
ragmented RNA to induce NF-B activation, pre-treatment of
/Brisbane/60/2008 MPH  with phospholipase C (Lipase) reduced
F-B activation compared to untreated control (Fig. 4B).
gain, RNase A- and Benzonase-treated B/Brisbane/60/2008 MPH
oorly induced NF-B activation, whereas proteinase K (PK) and then tested (170 ng RNA/well) for the capacity to induce NFB activation (O.D.
pre-treatment had no effect (despite reducing protein con-Fig. 3. Analysis of NF-B signalling capacity of RNA fragments extracted from CSL
TIVs. RNA (170 ng RNA/well) isolated from the CSL TIVs and MPHs (as indicated) was
tested in the NF-B HEK 293 cell assay (O.D. 405 nm)  either alone (left panel) or in
the presence of Lipofectamine® 2000 (right panel).
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Fig. 4. Analysis of NF-B signalling capacity of RNA fragments extracted from CSL
TIVs or B/Brisbane/60/2008 MPH  following treatment with heat or nucleases. (A)
CSL 2010 SH TIV was heated to either 56 ◦C, 65 ◦C or 90 ◦C for 30 mins, cooled to
room temperature and then incubated with RNaseA prior to testing in the NF-B
HEK 293 cell assay (O.D. 405 nm)  either alone or in the presence of Lipofectamine®
2000 as indicated. (B) Induction of NF-B activation (O.D. 405 nm) in NF-B HEK 293
cells  in response to B/Brisbane/60/2008 MPH  following enzymatic treatment with
proteinase (Proteinase K), lipase (Phospholipase C), nuclease (RNase A, benzonase)
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wr  combinations thereof. All samples were tested in triplicate in at least two inde-
endent assays. Statistically signiﬁcant changes between test and respective control
p  < 0.01) are noted by *.
.4. Increasing the level of TDOC used for splitting quenches
F-B and cytokine/chemokine signalling
Inactivated TIVs are chemically disrupted with either deter-
ent or solvent [26] to reduce the incidence of systemic reactions
s compared to whole virus vaccines. In order to investigate
he effect of varying the level of detergent used for splitting
he inactivated virus, three re-engineered CSL 2011/12 NH TIVs
ere generated and tested for their capacity to activate NF-B
n NF-B HEK 293 cells (Fig. 5A) and in the paediatric WBA
Fig. 5B). In the standard CSL 2011/12 NH TIV, A/California/07/2009,
/Victoria/210/2009 and B/Brisbane/60/2008 were split with 0.9%,
.5% and 0.5% TDOC respectively. In the CSL 2011/12 NH New#1 TIV,
/California/07/2009 was split at 1.5% TDOC instead of 0.9% whilst
DOC levels for A/Victoria/210/2009 and B/Brisbane/60/2008
emained unaltered (i.e. 1.5% and 0.5% respectively). In the CSL
011/12 NH New#2 TIV, B/Brisbane/60/2008 was split using 1.5%
DOC instead of 0.5% whilst TDOC levels for A/California/07/2009
nd A/Victoria/210/09 remained unaltered (i.e. 0.9% and 1.5%
espectively). Lastly, in the CSL 2011/12 NH New#3 TIV, all 3 MPHs
ere split with 1.5% TDOC.2 (2014) 3869–3876 3873
As shown in Fig. 5A, the CSL 2011/12 NH New#1 TIV induced
a moderate reduction in NF-B activation (25%) compared to the
standard CSL 2011/12 NH TIV. In contrast, the CSL 2011/12 NH
New#2 TIV, where B/Brisbane/60/2008 was split using 1.5% TDOC
(instead of 0.5%), poorly activated NF-B (Fig. 5A). Finally, NF-
B activation was  completely abrogated in the CSL 2011/12 NH
New#3 TIV (all 3 MPHs split at 1.5% TDOC) (Fig. 5A). In addition,
the strong NF-kB activation induced by B/Brisbane/60/2008 MPH
(split with 0.5% TDOC) was dramatically reduced when split at
1.5% TDOC (Fig. 5A). These results were paralleled in the paediatric
WBAs, with a marked reduction in the induction of IL-1 and other
cytokines/chemokines in response to the CSL 2011/12 NH New#2
TIV and CSL 2011/12 NH New#3 (Fig. 5B). Importantly, this decrease
in NF-B signal and cytokine/chemokine secretion with increasing
%TDOC used for splitting was also associated with a concomitant
decrease in both the total RNA (Fig. 5C) and lipid content (Fig. 5D).
Fig. 6 depicts how the host immune system recognises speciﬁc
viral components present in CSL TIVs. Our ﬁndings indicate that
CSL’s standard method of manufacture retains split virus compo-
nents that facilitate lipid-mediated delivery of fragmented, viral
RNA to host APCs and detection by cytoplasmic PRRs. This elicits
NF-B activation, cytokine/chemokine release resulting in immune
activation and generation of protective Ab responses to the TIV
strains. However, in the 2010 SH season, the particular charac-
teristics of the virus components from the new strains, elicited
an excessive immune response in some children <5 years, trigg-
ering increased fever and fever-related convulsions. Importantly,
Figs. 5C and D indicate that these viral components can be substan-
tially reduced by increasing the % TDOC detergent used during viral
splitting of the B strain and to a lesser extent the H1N1 A strain.
4. Discussion
The CSL 2010 SH TIV was  associated with an unexpected
increase in post-marketing reports of fever and febrile convulsions
in children <5 years of age, compared to previous seasons TIVs.
Our scientiﬁc investigations incorporated the use of animal models
(mice, newborn rats, rabbits, ferrets and infant non-human pri-
mates) as well as in vitro assays as surrogates of in vivo pyrogenicity.
The various TIVs tested were unable to elicit a fever response in
the animal models so focus turned to the in vitro assays. In an
accompanying study [9], we  describe that although CSL TIVs, as
a class, elicited higher levels of cytokine/chemokines in vitro in
paediatric WBAs as compared to 2010 SH TIVs produced by other
manufacturers, a small proportion of paediatric donors responded
more vigorously to the CSL 2010 SH TIV when compared to pre-
vious season’s CSL TIVs. This suggested that this subset of donors
was particularly sensitive to components within the CSL 2010 SH
TIV as compared to previous season’s CSL TIVs. The data also indi-
cate that the introduction of the H1N1 A/California/07/2009 (and
to a much lesser degree, H3N2 A/Wisconsin/15/2009) in combi-
nation with B/Brisbane/60/2008 combined and likely compounded
the bioactivity of the CSL 2010 SH TIV. This was  associated with
stronger immune responses, which in a proportion of children <5
years were associated with FS [9].
The present study extended upon these ﬁndings with the
aim to identify the speciﬁc characteristics of the components
that were preserved within the CSL method of manufacture.
The ﬁndings point to the lipid-mediated delivery of fragmented
RNA to APCs resulting in elicitation of stronger than expected
cytokine/chemokine secretion and NF-B activation, which in a
proportion of children <5 years were associated with FS. Nucle-
ase treatment of the CSL 2010 SH TIV abrogated the induction
of NF-B and cytokine/chemokine responses, thus strongly impli-
cating viral RNA as the key contributor to the pyrogenic signal
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Fig. 5. Effect of the level of TDOC detergent used upon cytokine induction, NF-B signalling, RNA content and lipid content. (A) Induction of NF-B activation (O.D. 405 nm)
in  NF-B HEK 293 cells in response to standard (TIV) and re-engineered CSL 2011/12 NH TIVs (New#1, New#2, New#3) prepared using higher levels of TDOC for splitting (as
described). Statistically signiﬁcant changes between test and respective control (p < 0.01) are noted by *. The results displayed are representative of one of two  independent
experiments performed in triplicate. (B) Induction of IL-1 secretion in the paediatric WBAs. Data presented are duplicate determinations from three donors. (C) RNA content
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ssociated with the increased post marketing reports of FS in chil-
ren <5 years. The observation that RNA extracted from either
he CSL 2010 SH TIV or B/Brisbane/60/2008 MPH  alone did not
nduce an NF-B signal in the NF-B HEK 293 cell line unless
ipid was available to mediate delivery (such as Lipofectamine®
000) suggests that viral lipid facilitated the uptake/delivery of
he RNA to access cytoplasmic PRRs. The important role of lipid
as also conﬁrmed by the reduction of NF-B signalling fol-
owing lipase treatment of TIVs or MPHs. Furthermore, the lost
ignalling capacity of CSL 2010 SH TIV and B/Brisbane/60/2008 MPH
eated to >65 ◦C was restored by the addition of Lipofectamine®
000, suggesting that the interaction between TIV-RNA and lipid
s heat labile. The connection between the presence of RNA and
nduction of a pyrogenic signal is further strengthened by the
bservation that the Comparator A 2010 SH TIV, which was
ot associated with FS in children <5 years, did not contain
etectable levels of RNA and does not signal in these same in vitro
ssays.There are several lines of evidence that implicate a compound-
ng effect of the new strains introduced into the CSL 2010 SH TIV.
he contribution of A/California/07/2009 is demonstrated by the
act that as with B/Brisbane/60/2008, A/California/07/2009 is atergent (• cholesterol, x sphinogmyelin and  DPPC). All samples were tested in
strong inducer of cytokine/chemokines in the paediatric WBAs
[9]. Furthermore, when A/California/07/2009 was substituted
by the previous season’s H1N1 strain, A/Brisbane/59/2007 in a
re-engineered CSL 2010 SH TIV, it elicited signiﬁcantly lower
levels of cytokine/chemokines in the paediatric WBAs [9]. How-
ever, CSL TIVs formulated with increased levels of TDOC for the
B/Brisbane/60/2008 strain (1.5% instead of 0.5%) resulted in the
largest decrease in pro-inﬂammatory signals in vitro, suggesting
that the primary issue was  how the B strain components interact
with the A strain and that disrupting the B strain was key to
addressing the reactogenicity issue. It was also observed that
increasing % TDOC used for splitting several different B strains
inversely correlated with the level of lipid content detected.
Together, these observations are consistent with lipid-mediated
delivery of RNA fragments being the primary mechanism by which
the CSL TIVs and MPHs can induce a response in the in vitro sur-
rogate assays and that B/Brisbane/60/2008, in particular, and to a
lesser degree A/California/07/2009 were likely the major contribut-
ing strains that combined and compounded this signal. Finally,
although residual whole virus has been reported as contributing to
the pyrogenicity of TIVs, exhaustive studies by CSL to elucidate the
role of residual whole virus indicate that although residual whole
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pig. 6. Schematic depicting lipid-mediated delivery of RNA to host APCs. CSL’s sta
o  be taken up and recognised by host APCs via various PRRs (e.g. endosomic TLRs 
gainst the three strains of Inﬂuenza contained in the TIV. However, in the 2010 SH
xpressed in the CSL 2010 TIV, elicited an excessive immune response in some chil
irus can contribute to the pro-inﬂammatory signal in the in vitro
ssays described, the majority of the pro-inﬂammatory signal is
erived from the smaller sized, split viral complexes (composed of
NA, protein and lipid) (manuscript in preparation).
The root cause investigations into the increase in reports of FS
ssociated with the CSL 2010 SH TIV have identiﬁed lipid-mediated
elivery of inﬂuenza virus-derived RNA fragments as the likely
ontributing factors. At this stage, the available data suggests that
he levels of RNA and lipid in the CSL 2010 SH TIV differ moder-
tely from previous seasons CSL TIVs. Ongoing lines of investigation
nclude assessing qualitative differences between the RNA and lipid
ontent of B/Brisbane/60/2008 and A/California/07/2009 MPHs as
ompared to previous and more recent B and H1N1 TIV strains.
nitial data suggests that the B/Brisbane/60/2008 strain displays
reater RNA/protein association and that the RNA is more resis-
ant to nuclease digestion as compared to other B strains examined
manuscript in preparation). In addition, differences in the propor-
ion of RNA species (e.g. ssRNA vs dsRNA) in the different MPHs may
e informative, as these are recognised by different PRRs expressed
y APCs in whole blood potentially resulting in differing signal
trengths in vivo.
More importantly, the data identiﬁes a potential path for-
ard for generating a CSL TIV indicated for use in children
5 years. Irrespective of a complete understanding of the exact
echanism by which the RNA in the B/Brisbane/60/2008 and/or
/California/07/2009 MPH  delivers the pyrogenic signal in vitro,
t is possible to quench the signal by increasing the level of
DOC used for splitting the B strain which in turn decreases the
evel of lipid present in the vaccine. Such adjustments are within
SL’s approved manufacturing speciﬁcation and pilot scale stud-
es have demonstrated that increasing the TDOC concentration
sed for splitting the B strain is feasible. CSL will be incorporat-
ng an increase in the concentration of TDOC used for splitting
ll future B strains into the currently approved manufacturing
rocess. The in vitro assays described will be used to evaluate
he pyrogenic potential of new inﬂuenza strains and to gauge
he effects of increasing detergent strength during splitting. CSL
ntends to demonstrate the safety and immunogenicity of this mod-
ﬁcation for the paediatric population via a multi-stage clinical
rogramme. method of manufacture allows lipid-mediated delivery of fragmented, viral RNA
ytosolic PRRs). This results in the generation of protective Ab-mediated immunity
on, the particular characteristics of the virus components from the new strains, as
5 years, triggering increased fever and fever-related convulsions.
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